A potential precision medicine approach for treating vision loss
Columbia University Medical Center (CUMC) and University of Iowa scientists have used a new gene-editing technology called CRISPR to repair a genetic mutation responsible for retinitis pigmentosa (RP), an inherited condition that causes the retina to degrade and leads to blindness in at least 1.5 million cases worldwide.
The study was published in Scientific Reports, and marks the first time researchers have replaced a defective gene associated with a sensory disease in stem cells that were derived from a patient’s tissue.
“Our vision is to develop a personalized approach to treating eye disease,” says Stephen Tsang, MD, PhD, the László Z. Bitó Associate Professor of Ophthalmology and associate professor of Pathology & Cell Biology at CUMC, ophthalmologist at NewYork-Presbyterian/Columbia, and one of the study’s senior authors. “We still have some way to go, but we believe that the first therapeutic use of CRISPR will be to treat an eye disease. Here we have demonstrated that the initial steps are feasible.”
In the study, the researchers created stem cells from a sample of skin that was taken from a patient with retinitis pigmentosa. As the patient-derived stem cells still harbored the disease-causing mutation, the teams used CRISPR to repair the defective gene. The stem cells can potentially be transformed into healthy retinal cells and transplanted back into the same patient to treat vision loss.
“The X-linked form of retinitis pigmentosa is an ideal candidate for a precision medicine approach because a common mutation accounts for 90% cases,” Tsang explains. Using CRISPR —which is easily adaptable to diverse sequences of DNA, and allows for fast and accurate editing —scientists can take a patient’s own cells and make pinpoint repairs specific to that individual’s genome.
Because the corrections are made in cells derived from the patient’s own tissue, doctors can re-transplant the cells with fewer fears of rejection by the immune system. Previous clinical trials have shown that generating retinal cells from embryonic stem cells and using them for transplantation is a safe and potentially effective procedure.
In this paper, the researchers targeted one of the most common variants of retinitis pigmentosa, which is caused by a single mistake in a gene called RGPR. The composition of RGPR—which contains many repeats and tight-binding nucleotide pairs—make it a difficult gene to edit. The researchers say that preliminary success with RGPR is therefore promising for treating other forms of the condition caused by mutations in other genes.
The current treatment for retinitis pigmentosa recommended by the National Institutes of Health—consuming high doses of vitamin A—slows down vision loss but does not cure the disease.
Other types of gene therapies for are currently undergoing clinical trials. Unlike CRISPR-based methods, these therapies introduce stretches of DNA that supplement some of the activity of the defective gene, but do not directly correct the original mutation. Follow-up studies have shown that any gains in vision from these gene supplementation therapies wane over time.
A CRISPR-driven precision medicine approach to treating retinitis pigmentosa may improve upon current therapies and restore a patient’s vision because CRISPR, with its pinpoint accuracy, can correct the fundamental genetic defect responsible for the disease. However, CRISPR technology has not yet been approved for use in humans.
The Latest on: Retinitis pigmentosa
via Google News
The Latest on: Retinitis pigmentosa
- Dr. Kang Zhang and Team Demonstrate Promising Gene Therapy Treatment for Retinitis Pigmentosaon November 6, 2019 at 5:55 am
Dr. Kang Zhang M.D. Ph.D. who is known for his breakthrough research in ophthalmic genetics released a manuscript in Nature highlighting a novel gene therapy that can be applied to degenerative ...
- Retinitis Pigmentosa Treatment Market Capacity, Production, Sales, Consumption, Status and Forecast 2019-2026on October 9, 2019 at 7:11 am
Oct 09, 2019 (Market Prediction via COMTEX) -- In 2018, the Retinitis Pigmentosa Treatment Market revenue was around US$ XX Mn and the Market share was XX%,... Oct 09, 2019 (Market Prediction via ...
- ReNeuron looks to follow up retinitis pigmentosa studieson October 7, 2019 at 1:34 pm
A Phase I/II assessment of a very small group of sufferers of a blindness-causing disease called retinitis pigmentosa saw a significant improvement in vision after treatment. Six months after ...
- Full interview: 'All systems go' for ReNeuron's retinitis pigmentosa programme as it looks to follow-up studieson October 7, 2019 at 4:30 am
ReNeuron Group PLC's (LON:RENE) Michael Hunt tells Proactive London's Andrew Scott they've seen a 'rapid and profound' result in the first three patients of the second phase of clinical studies of its ...
- ReNeuron Reports Mixed Results For Retinitis Pigmentosa Trialon October 2, 2019 at 8:15 am
(Alliance News) - ReNeuron Group PLC on Wednesday posted positive results from early patients in its ongoing trial of a treatment for retinitis pigmentosa, which causes blindness, but was less ...
- ReNeuron hails "clear signal" from retinitis pigmentosa trialson October 2, 2019 at 1:08 am
The Phase 2a trials of hRPC in sufferers of a blindness-causing disease called retinitis pigmentosa has seen noticeable improvements in visual acuity as measured by the number of letters that could be ...
- ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosaon September 8, 2019 at 5:00 pm
QR-1123 is a first-in-class investigational antisense oligonucleotide designed to address the underlying cause of vision loss associated with autosomal dominant retinitis pigmentosa (adRP) due to the ...
- Clinical Characterization of Retinitis Pigmentosa Associated With Variants in SNRNP200on September 4, 2019 at 5:00 pm
1 Nuffield Laboratory of Ophthalmology, Department of Clinical Neurosciences, Oxford University, John Radcliffe Hospital, Oxford, United Kingdom 2 Oxford Eye Hospital, John Radcliffe Hospital, Oxford ...
- Retinitis Pigmentosa (RP) Market 2017 Global Industry Size, Growth, Segments, Revenue, Manufacturers and 2025 Forecaston August 20, 2019 at 6:58 am
Retinitis pigmentosa, in which patients usually lose night vision in teenage years, side vision in middle age, and central vision in later life because of steady loss of cone photoreceptor cells and ...
via Bing News